top of page

May 3, 2024

Screenshot 2024-05-03 at

ShangBay Capital’s William Dai Recognized Among GrowthCap’s Top 25 Healthcare Investors for 2024

ShangBay Capital celebrates William Dai's recognition as one of GrowthCap's top healthcare investors for 2024. Dai, ShangBay's Founding Managing Partner, is praised for his impactful investments in medtech ventures, showcasing over two decades of finance and mergers expertise. With 67 nurtured portfolio companies and numerous successful exits, Dai's leadership highlights ShangBay's commitment to supporting innovative healthcare solutions amidst global challenges.

April 22, 2024

Screenshot 2024-04-22 at

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration

Ipsen and Skyhawk Therapeutics have teamed up to develop groundbreaking treatments for rare neurological diseases using Skyhawk's RNA-targeting platform. Ipsen will handle further development and commercialization, with Skyhawk potentially receiving up to $1.8 billion in milestones and royalties. This partnership underscores a significant investment in innovative therapies for patients with unmet medical needs in the field of rare neurological disorders.

February 28, 2024

Screenshot 2024-03-08 at

Skyhawk Therapeutics Progresses SKY-0515 Study in Huntington's Disease

Skyhawk Therapeutics, Inc. announces Phase 1 MAD initiation for SKY-0515 in Huntington's disease. Derived from their SKYSTAR® platform, SKY-0515 targets mutated huntingtin protein, offering potential benefits to patients lacking curative therapies. This marks a significant milestone in Skyhawk's quest for breakthrough treatments.

February 26, 2024

Screenshot 2024-02-29 at 1.58_edited.jpg

Laplace Interventional Announces Successful First in Human Procedure in Early Feasibility Study

Laplace Interventional, in collaboration with the Tucson Medical Center, achieved a medical breakthrough with the first-in-human implantation of its Transcatheter Tricuspid Valve Replacement (TTVR) system, targeting Tricuspid Regurgitation (TR). This minimally invasive procedure, conducted under FDA-approved study protocols, signals a promising advancement in cardiac care.

February 14, 2024

Screenshot 2024-02-14 at 4.59.35 PM.png

Neuro42 Receives FDA Clearance on Portable and Compact Brain MRI Scanner for Point of Care Imaging

Neuro42, a medical technology company, has obtained FDA clearance for its portable MRI scanner, eliminating the need for patient transport and improving diagnosis and treatment for neurological conditions. With a focus on accessibility and innovation, neuro42 aims to launch its MRI system in the US market this year, revolutionizing neuroimaging and surgical guidance.

February 2, 2024

Avation Medical.jpg

Avation Medical raises $22M+ from impressive line-up of new global investors

Avation Medical, an innovative neuromodulation and digital health company, announced more than $22 million in equity financing in its oversubscribed Series C round, led by new investors ShangBay Capital and Asahi Kasei, which included Angelini Ventures, JobsOhio Growth Capital Fund, and others.

Janurary 17, 2024


2023 SVB Health Care Report

Shangbay Capital has been ranked the most-active healthcare device investor by Silicon Valley Bank in their 2023 Healthcare Annual Report.

January 4, 2024


HSBC Venture Healthcare Report 2023

Shangbay Capital has been ranked the #2 most-active healthcare device investor by the 2023 HSBC Healthcare Annual Report.

bottom of page